What is the share price of Astrazeneca Pharma India Ltd (ASTRAZEN) today?
The share price of ASTRAZEN as on 11th July 2025 is ₹9241.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Astrazeneca Pharma India Ltd (ASTRAZEN) share?
The past returns of Astrazeneca Pharma India Ltd (ASTRAZEN) share are- Past 1 week: 0.23%
- Past 1 month: -8.71%
- Past 3 months: 9.27%
- Past 6 months: 30.83%
- Past 1 year: 34.36%
- Past 3 years: 212.02%
- Past 5 years: 176.61%
What are the peers or stocks similar to Astrazeneca Pharma India Ltd (ASTRAZEN)?
The peers or stocks similar to Astrazeneca Pharma India Ltd (ASTRAZEN) include:What is the market cap of Astrazeneca Pharma India Ltd (ASTRAZEN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astrazeneca Pharma India Ltd (ASTRAZEN) is ₹23103.75 Cr as of 11th July 2025.What is the 52 week high and low of Astrazeneca Pharma India Ltd (ASTRAZEN) share?
The 52-week high of Astrazeneca Pharma India Ltd (ASTRAZEN) is ₹10691 and the 52-week low is ₹6220.What is the PE and PB ratio of Astrazeneca Pharma India Ltd (ASTRAZEN) stock?
The P/E (price-to-earnings) ratio of Astrazeneca Pharma India Ltd (ASTRAZEN) is 199.62. The P/B (price-to-book) ratio is 32.45.Which sector does Astrazeneca Pharma India Ltd (ASTRAZEN) belong to?
Astrazeneca Pharma India Ltd (ASTRAZEN) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Astrazeneca Pharma India Ltd (ASTRAZEN) shares?
You can directly buy Astrazeneca Pharma India Ltd (ASTRAZEN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Astrazeneca Pharma India Ltd
ASTRAZEN Share Price
ASTRAZEN Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ASTRAZEN Performance & Key Metrics
ASTRAZEN Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
199.62 | 32.45 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
36.72 | 6.42 | 0.79% |
ASTRAZEN Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
ASTRAZEN Company Profile
AstraZeneca Pharma India Limited is a biopharmaceutical company engaged in the discovery, development and commercialization of medicines for core areas of healthcare.
ASTRAZEN Forecast
ASTRAZEN Forecasts
ASTRAZEN
ASTRAZEN
Income
Balance Sheet
Cash Flow
ASTRAZEN Income Statement
ASTRAZEN Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 558.10 | 583.25 | 744.58 | 844.80 | 826.40 | 820.36 | 1,029.07 | 1,346.76 | 1,756.92 | 1,756.92 | ||||||||||
Raw Materials | 155.96 | 231.52 | 232.51 | 344.44 | 292.00 | 297.49 | 408.84 | 628.33 | 1,559.11 | 1,559.11 | ||||||||||
Power & Fuel Cost | 7.68 | 8.30 | 8.27 | 7.72 | 7.37 | 8.10 | 5.54 | 4.87 | ||||||||||||
Employee Cost | 162.04 | 150.39 | 197.40 | 216.70 | 219.54 | 230.21 | 259.10 | 241.45 | ||||||||||||
Selling & Administrative Expenses | 144.27 | 168.54 | 198.14 | 157.18 | 129.72 | 145.09 | 185.72 | 234.33 | ||||||||||||
Operating & Other expenses | 36.82 | -34.04 | 20.67 | -14.93 | 29.46 | 38.53 | 18.88 | 2.10 | ||||||||||||
EBITDA | 51.33 | 58.54 | 87.59 | 133.69 | 148.31 | 100.94 | 150.99 | 235.68 | 197.81 | 197.81 | ||||||||||
Depreciation/Amortization | 15.83 | 14.74 | 14.92 | 18.58 | 20.13 | 16.95 | 16.26 | 14.94 | 39.99 | 39.99 | ||||||||||
PBIT | 35.50 | 43.80 | 72.67 | 115.11 | 128.18 | 83.99 | 134.73 | 220.74 | 157.82 | 157.82 | ||||||||||
Interest & Other Items | 0.00 | 0.00 | 0.00 | 1.14 | 1.09 | 0.95 | 0.63 | 1.20 | 1.46 | 1.46 | ||||||||||
PBT | 35.50 | 43.80 | 72.67 | 113.97 | 127.09 | 83.04 | 134.10 | 219.54 | 156.36 | 156.36 | ||||||||||
Taxes & Other Items | 15.45 | 17.89 | 18.22 | 41.76 | 33.79 | 21.44 | 34.81 | 58.03 | 40.62 | 40.62 | ||||||||||
Net Income | 20.05 | 25.91 | 54.45 | 72.21 | 93.30 | 61.60 | 99.29 | 161.51 | 115.74 | 115.74 | ||||||||||
EPS | 8.02 | 10.36 | 21.78 | 28.88 | 37.32 | 24.64 | 39.72 | 64.60 | 46.30 | 46.30 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 1.00 | 2.00 | 10.00 | 16.00 | 24.00 | 0.00 | 24.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.03 | 0.05 | 0.41 | 0.40 | 0.37 | 0.00 | 0.52 |
ASTRAZEN Company Updates
ASTRAZEN Stock Peers
ASTRAZEN Past Performance & Peer Comparison
ASTRAZEN Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Astrazeneca Pharma India Ltd | 199.62 | 32.45 | — |
Sun Pharmaceutical Industries Ltd | 36.71 | 5.53 | 0.96% |
Cipla Ltd | 22.75 | 3.83 | 1.08% |
Torrent Pharmaceuticals Ltd | 58.69 | 14.78 | 0.18% |
ASTRAZEN Stock Price Comparison
Compare ASTRAZEN with any stock or ETFASTRAZEN Holdings
ASTRAZEN Shareholdings
ASTRAZEN Promoter Holdings Trend
ASTRAZEN Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
ASTRAZEN Institutional Holdings Trend
ASTRAZEN Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
ASTRAZEN Shareholding Pattern
ASTRAZEN Shareholding Pattern
ASTRAZEN Shareholding History
ASTRAZEN Shareholding History
Mutual Funds Invested in ASTRAZEN
Mutual Funds Invested in ASTRAZEN
No mutual funds holding trends are available
Top 5 Mutual Funds holding Astrazeneca Pharma India Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.5374% | Percentage of the fund’s portfolio invested in the stock 0.88% | Change in the portfolio weight of the stock over the last 3 months -0.14% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 26/248 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2582% | Percentage of the fund’s portfolio invested in the stock 3.70% | Change in the portfolio weight of the stock over the last 3 months -0.33% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 3/91 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2413% | Percentage of the fund’s portfolio invested in the stock 0.65% | Change in the portfolio weight of the stock over the last 3 months -0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 34/40 (-1) |
Compare 3-month MF holding change on Screener
smallcases containing ASTRAZEN stock
smallcases containing ASTRAZEN stock
Looks like this stock is not in any smallcase yet.
ASTRAZEN Events
ASTRAZEN Events
ASTRAZEN Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
ASTRAZEN Dividend Trend
No dividend trend available
ASTRAZEN Upcoming Dividends
ASTRAZEN Upcoming Dividends
No upcoming dividends are available
ASTRAZEN Past Dividends
ASTRAZEN Past Dividends
Cash Dividend
Ex DateEx DateJul 5, 2024
Dividend/Share
₹24.00
Ex DateEx Date
Jul 5, 2024
Cash Dividend
Ex DateEx DateJul 14, 2023
Dividend/Share
₹16.00
Ex DateEx Date
Jul 14, 2023
Cash Dividend
Ex DateEx DateJul 7, 2022
Dividend/Share
₹8.00
Ex DateEx Date
Jul 7, 2022
Cash Dividend
Ex DateEx DateAug 18, 2021
Dividend/Share
₹2.00
Ex DateEx Date
Aug 18, 2021
Cash Dividend
Ex DateEx DateAug 20, 2020
Dividend/Share
₹2.00
Ex DateEx Date
Aug 20, 2020
ASTRAZEN Stock News & Opinions
ASTRAZEN Stock News & Opinions
AstraZeneca Pharma India has fixed 18 July 2025 as record date for final dividend for FY 2024-25. The dividend, if approved, will be paid on or before 12 September 2025. Powered by Capital Market - Live
AstraZeneca Pharma India has fixed 18 July 2025 as record date for determining the entitlement of the shareholders for the payment of Final Dividend for the financial year 2024-25. The dividend, if approved, shall be paid on or before 12 September 2025. Powered by Capital Market - Live
Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR). AstraZeneca Pharma is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. The company's consolidated net profit jumped 57.7% to Rs 62.27 crore on 25.4% increase in net sales to Rs 480.48 crore in Q4 FY25 over Q4 FY24. The scrip shed 0.13% to end at Rs 8,886.50 on the BSE.Powered by Capital Market - Live
Orient Cement Ltd, India Cements Ltd, Concord Biotech Ltd and ERIS Lifesciences Ltd are among the other losers in the BSE's 'A' group today, 20 June 2025.Astrazeneca Pharma India Ltd crashed 4.50% to Rs 8998.95 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 4557 shares were traded on the counter so far as against the average daily volumes of 7605 shares in the past one month.Orient Cement Ltd lost 4.49% to Rs 233.95. The stock was the second biggest loser in 'A' group.On the BSE, 99812 shares were traded on the counter so far as against the average daily volumes of 77687 shares in the past one month.India Cements Ltd tumbled 4.09% to Rs 307.25. The stock was the third biggest loser in 'A' group.On the BSE, 22631 shares were traded on the counter so far as against the average daily volumes of 34658 shares in the past one month.Concord Biotech Ltd plummeted 3.89% to Rs 1891.9. The stock was the fourth biggest loser in 'A' group.On the BSE, 3262 shares were traded on the counter so far as against the average daily volumes of 12882 shares in the past one month.ERIS Lifesciences Ltd shed 3.38% to Rs 1676.65. The stock was the fifth biggest loser in 'A' group.On the BSE, 4219 shares were traded on the counter so far as against the average daily volumes of 15943 shares in the past one month.Powered by Capital Market - Live
Panchal is set to transition to a global role within the AstraZeneca Group, based in Gaithersburg, Maryland, US. The board acknowledged his resignation and placed on record its appreciation for his contributions during his tenure. Following the recommendation of the nomination and remuneration committee, the board has approved the appointment of Praveen Rao Akkinepally as the new MD. He will take charge from 1 July 2025, for a term of three years. Akkinepally is a senior commercial leader with over two decades of experience across the US, global markets, and India, particularly in oncology and biopharmaceuticals. He has led several brand launches and driven global commercial strategies at AstraZeneca. His previous role as oncology business unit head for India saw significant growth in the company's market presence and a series of successful oncology product launches. Beyond his corporate achievements, he has contributed to healthcare policy through his work with the Federation of Indian Chambers of Commerce and Industry's cancer round tables. Akkinepally holds an MBA from the University of Michigan's Ross School of Business and a master's in public health from Johns Hopkins University. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. The company's standalone net profit rose 47.54% to Rs 58.25 crore, while revenue from operations rose 25.39% to Rs 480.48 crore in Q4 March 2025 over Q4 March 2024. Powered by Capital Market - Live
Niva Bupa Health Insurance Company Ltd, Indian Overseas Bank, Sterling & Wilson Renewable Energy Ltd, Capri Global Capital Ltd are among the other stocks to see a surge in volumes on NSE today, 02 June 2025.Astrazeneca Pharma India Ltd registered volume of 7.73 lakh shares by 14:14 IST on NSE, a 62.2 fold spurt over two-week average daily volume of 12432 shares. The stock rose 12.66% to Rs.8,981.00. Volumes stood at 15250 shares in the last session.Niva Bupa Health Insurance Company Ltd saw volume of 1498.24 lakh shares by 14:14 IST on NSE, a 26.47 fold spurt over two-week average daily volume of 56.61 lakh shares. The stock dropped 9.76% to Rs.83.28. Volumes stood at 59.61 lakh shares in the last session.Indian Overseas Bank notched up volume of 800.38 lakh shares by 14:14 IST on NSE, a 7.74 fold spurt over two-week average daily volume of 103.44 lakh shares. The stock rose 4.89% to Rs.41.79. Volumes stood at 303.39 lakh shares in the last session.Sterling & Wilson Renewable Energy Ltd recorded volume of 84.57 lakh shares by 14:14 IST on NSE, a 7.49 times surge over two-week average daily volume of 11.30 lakh shares. The stock gained 9.22% to Rs.308.45. Volumes stood at 8.71 lakh shares in the last session.Capri Global Capital Ltd registered volume of 38.42 lakh shares by 14:14 IST on NSE, a 6.49 fold spurt over two-week average daily volume of 5.92 lakh shares. The stock rose 3.01% to Rs.156.26. Volumes stood at 12.3 lakh shares in the last session.Powered by Capital Market - Live
Sun Pharma Advanced Research Company Ltd, Bank of Maharashtra, Reliance Power Ltd and Genus Power Infrastructures Ltd are among the other gainers in the BSE's 'A' group today, 02 June 2025.Astrazeneca Pharma India Ltd spiked 11.17% to Rs 8855 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 24613 shares were traded on the counter so far as against the average daily volumes of 920 shares in the past one month. Sun Pharma Advanced Research Company Ltd soared 10.07% to Rs 203.8. The stock was the second biggest gainer in 'A' group. On the BSE, 3.28 lakh shares were traded on the counter so far as against the average daily volumes of 69764 shares in the past one month. Bank of Maharashtra surged 6.93% to Rs 57.73. The stock was the third biggest gainer in 'A' group. On the BSE, 52.36 lakh shares were traded on the counter so far as against the average daily volumes of 12.82 lakh shares in the past one month. Reliance Power Ltd rose 6.09% to Rs 61.7. The stock was the fourth biggest gainer in 'A' group. On the BSE, 375.97 lakh shares were traded on the counter so far as against the average daily volumes of 158.73 lakh shares in the past one month. Genus Power Infrastructures Ltd advanced 5.94% to Rs 418.45. The stock was the fifth biggest gainer in 'A' group. On the BSE, 4.95 lakh shares were traded on the counter so far as against the average daily volumes of 1.27 lakh shares in the past one month. Powered by Capital Market - Live
Max Healthcare Institute Ltd, Godrej Consumer Products Ltd, Mphasis Ltd, Indraprastha Gas Ltd are among the other stocks to see a surge in volumes on BSE today, 02 June 2025.Astrazeneca Pharma India Ltd recorded volume of 20063 shares by 10:46 IST on BSE, a 24.47 times surge over two-week average daily volume of 820 shares. The stock gained 11.18% to Rs.8,855.50. Volumes stood at 1496 shares in the last session.Max Healthcare Institute Ltd saw volume of 11.56 lakh shares by 10:46 IST on BSE, a 11.71 fold spurt over two-week average daily volume of 98752 shares. The stock increased 2.21% to Rs.1,149.85. Volumes stood at 19937 shares in the last session.Godrej Consumer Products Ltd registered volume of 58939 shares by 10:46 IST on BSE, a 8.21 fold spurt over two-week average daily volume of 7182 shares. The stock rose 2.53% to Rs.1,262.60. Volumes stood at 2591 shares in the last session.Mphasis Ltd saw volume of 25982 shares by 10:46 IST on BSE, a 4.14 fold spurt over two-week average daily volume of 6282 shares. The stock dropped 3.11% to Rs.2,480.00. Volumes stood at 4930 shares in the last session.Indraprastha Gas Ltd registered volume of 3.58 lakh shares by 10:46 IST on BSE, a 3.96 fold spurt over two-week average daily volume of 90342 shares. The stock rose 2.05% to Rs.211.10. Volumes stood at 84867 shares in the last session.Powered by Capital Market - Live
Profit before tax (PBT) stood at Rs 78.47 crore in Q4 FY25, up 44.35% year-on-year, and up 86.74% quarter-on-quarter. Total expenses rose 22.22% to Rs 412.48 crore in Q4FY25 over Q4FY24. During the quarter, cost of materials consumed stood at Rs 94.25 crore (up 180.34% YoY) while employee benefits expense was at Rs 66.07 crore (up 13.95% YoY). The company's net profit surged 88.82% while net sales rose 9.13% in Q4 March 2025 over Q3 December 2024. For the full year FY25, revenue from operations rose 32.48% to Rs 1,716.29 crore, while net profit fell 28.34% to Rs 115.74 crore. PBT fell 28.78% to Rs 156.36 crore compared to FY24. The company's standalone net cash from operating activities stood at Rs 65.36 crore in FY25, as against Rs 27.87 crore in FY24. Dr. Sanjeev Panchal, country president & managing director of the company, said, Our company delivered strong growth in Financial Year 2024-25 by launching innovative medicines in India, giving us momentum into 2025 and beyond. We are pleased to share that our company has, for the first time, crossed the INR 1,700 crore mark ($200 million). The board recommended dividend of Rs 32 per equity share for FY25. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. Powered by Capital Market - Live
Astrazeneca Pharma India Ltd gained 7.28% today to trade at Rs 8545.4. The BSE Healthcare index is up 0.34% to quote at 42749.54. The index is up 1.8 % over last one month. Among the other constituents of the index, Orchid Pharma Ltd increased 3.84% and Cohance Lifesciences Ltd added 1.94% on the day. The BSE Healthcare index went up 22.53 % over last one year compared to the 9.81% surge in benchmark SENSEX. Astrazeneca Pharma India Ltd has added 2.1% over last one month compared to 1.8% gain in BSE Healthcare index and 0.88% rise in the SENSEX. On the BSE, 1001 shares were traded in the counter so far compared with average daily volumes of 913 shares in the past one month. The stock hit a record high of Rs 9199 on 24 Apr 2025. The stock hit a 52-week low of Rs 5415.55 on 04 Jun 2024.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 15.77%, vs industry avg of 10%
Over the last 5 years, market share increased from 0.34% to 0.42%
Over the last 5 years, net income has grown at a yearly rate of 9.89%, vs industry avg of 19.96%